The Study
The Prophylactic Effect of Dexmedetomidine 0.008% Versus Brimonidine 0.2% on IOP Elevation After Nd: YAG Laser Capsulotomy
This study is like a fair race between two medicines to see which one stops eye pressure from going up after a laser treatment. It found that one medicine (brimonidine) did a better job than the other (dexmedetomidine). But it doesn't prove the weaker medicine works perfectly—it just shows it didn't do as well.
Analysis score
Maximum 90 for a randomized controlled trial.
Where the score came from
After laser treatment to fix cloudy vision from cataract surgery, eye pressure can spike and hurt your vision. Two eye drops were tested to see which one stops that spike better.
Where does this study sit?
Reviews of RCTs (Meta-analyses)
Max 100Randomized Trials
Max 90Reviews of Cohort Studies
Max 85Cohort Studies
Max 72Reviews of Case-Control Studies
Max 63Case-Control Studies
Max 58Cross-Sectional & Case Series
Max 50Expert Opinion
Max 571 / 100
Quality score
Participants are randomly assigned to treatment or control groups, minimizing bias. The gold standard for testing whether an intervention causes an effect.
Key takeaways
Summary
Based on the study abstract and findings.
- 1Yes — spikes above 10 mmHg can damage the optic nerve, so 9% vs.
- 22% is a big difference in real-world risk.
- 3Brimonidine lowered eye pressure by 3.5 points at 4 hours and 2.5 points at 24 hours.
- 4Dexmedetomidine made pressure go up by 0.8 points at 4 hours and 0.4 points at 24 hours.
- 59% of people on dexmedetomidine had dangerous pressure spikes (>10 points), compared to 2% on brimonidine.
Score breakdown, methodology, conflicts of interest, evidence analysis & raw study data
Publication
Journal
Pharmacology Research & Perspectives
Year
2026
Authors
P. Zakeri, Ghodrat Akhavanakbari, Habib Ojaghi, Firouz Amani
Related Content
Claims (6)
At 30 minutes after Nd:YAG laser capsulotomy, brimonidine 0.2% lowers intraocular pressure significantly, while dexmedetomidine 0.008% does not.
In patients who have had cataract surgery and receive Nd:YAG laser treatment, dexmedetomidine 0.008% leads to a 9% rate of intraocular pressure rising above 10 mmHg and a 7% rate above 30 mmHg at four hours after the procedure, while brimonidine 0.2% results in a 2% rate for both pressure thresholds.
After Nd:YAG laser eye surgery, a single drop of brimonidine 0.2% lowers eye pressure by about 3.5 mmHg at 4 hours and 2.5 mmHg at 24 hours, while a drop of dexmedetomidine 0.008% raises eye pressure by 0.8 mmHg at 4 hours and 0.4 mmHg at 24 hours.
Topical dexmedetomidine 0.008% reduces intraocular pressure less after Nd:YAG laser capsulotomy than it does in healthy individuals without prior eye surgery or inflammation.
Higher pressure inside the eye directly increases the chance of damage to the optic nerve, and lowering that pressure reduces the risk of such damage.
When used as a single eye drop before Nd:YAG laser eye surgery, dexmedetomidine 0.008% and brimonidine 0.2% do not cause systemic or eye-related side effects.
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.